Buy Neulasta Prefilled Syringe Online

Neulasta Prefilled Syringe UltraSafe Guard contains pegfilgrastim, a long-acting medicine used after certain chemotherapy regimens to help reduce the risk of infection linked with febrile neutropenia. It can be ordered for US delivery from Canada, with the dose and quantity chosen during ordering matched to your oncology team’s directions. The single-dose prefilled syringe format is designed for subcutaneous injection and includes a needle safety guard for handling after use.

Price, Strength, and Ordering Details

Neulasta prefilled syringe price can vary by package, supply source, and current pharmacy cost. The product is commonly recognized as Neulasta 6 mg/0.6 mL injection in a single-dose prefilled syringe, but you should match the strength, form, and quantity shown during ordering with the instructions from your cancer care team. If you are paying out of pocket, reviewing the cash price before each cycle can help you plan around chemotherapy dates.

Many people look for Neulasta prefilled syringe without insurance because pegfilgrastim products can be expensive in local channels. BorderFreeHealth supports cash-pay ordering through licensed pharmacies, and order details may be checked for completeness before the pharmacy prepares the medication. Pricing shown at checkout is the best place to confirm the current Neulasta 6 mg syringe cost for the quantity being requested.

Quick tip: Keep a written calendar of chemotherapy infusion dates, planned injection dates, and refill timing so the medication is available when the cycle requires it.

What Neulasta Treats

Neulasta is used to reduce the incidence of infection, as shown by febrile neutropenia, in people receiving myelosuppressive chemotherapy associated with a clinically significant risk of severe neutropenia. Neutropenia means the body has too few neutrophils, a type of white blood cell that helps fight infection. Febrile neutropenia means low neutrophils occur with fever, which can become urgent during cancer treatment.

This medicine is not chemotherapy. It does not treat cancer directly, and it is not an antibiotic. Instead, pegfilgrastim stimulates the bone marrow to make more neutrophils after chemotherapy suppresses blood cell production. For more background on the treatment risk it helps address, see febrile neutropenia and neutropenia.

Neulasta is not used for chemotherapy regimens with minimal myelosuppression. Suitability depends on the chemotherapy plan, prior blood counts, infection risk, treatment goals, and the timing of each cycle. Your oncology team decides whether pegfilgrastim support is appropriate for the regimen you are receiving.

How Pegfilgrastim Works

Pegfilgrastim is a long-acting granulocyte colony-stimulating factor, often shortened to G-CSF. This class tells the bone marrow to increase neutrophil production. The long-acting design allows many adults to receive one injection per chemotherapy cycle rather than daily short-acting injections, when that schedule fits the treatment plan.

After administration, neutrophil counts usually rise as the marrow responds. The exact blood count pattern differs by person and chemotherapy regimen. Blood tests during treatment help the care team understand how well counts are recovering and whether the current supportive care plan remains appropriate.

The UltraSafe guard is a device feature attached to the prefilled syringe. After the injection is completed, the guard is intended to cover the needle and lower the chance of accidental needlestick injury. This does not replace careful injection technique or proper sharps disposal.

Dosing Timing and Use Basics

The usual adult schedule described in labeling is one 6 mg subcutaneous injection once per chemotherapy cycle. It is generally administered at least 24 hours after cytotoxic chemotherapy and should not be given within 14 days before the next chemotherapy cycle. Do not use it within 24 hours before chemotherapy starts.

Timing matters because pegfilgrastim is meant to support neutrophil recovery after chemotherapy has been given. If an infusion is delayed, moved, or cancelled, the injection timing may also need to change. Contact the treating clinic before using the syringe if the planned schedule no longer matches the chemotherapy calendar.

The injection itself is typically quick, but preparation takes time. The syringe may need to sit at room temperature as directed in the official instructions, and the solution should be inspected before use. Do not shake the syringe. Do not use it if the liquid looks cloudy, discolored, or contains particles.

Prefilled Syringe Handling

The Neulasta single-dose prefilled syringe is for subcutaneous use only. Common injection areas for subcutaneous medicines include the abdomen, thigh, upper outer arm, or outer buttock area, depending on who is administering the dose and what the clinic teaches. Rotate sites as instructed to help reduce irritation.

Use aseptic technique and follow the manufacturer’s instructions for removing the syringe from its tray, checking the device, and activating the safety guard after injection. Do not recap the needle after use. Place the used syringe directly into an approved sharps container or a puncture-resistant container that follows local rules.

If the syringe is dropped, damaged, frozen, shaken vigorously, or exposed to conditions outside label instructions, contact a healthcare professional or pharmacy before using it. Do not attempt to transfer the contents into another syringe or save leftover liquid for a later dose.

Storage, Travel, and Shipping

Store the prefilled syringe in the refrigerator in its original carton to protect it from light. Do not freeze it. If the syringe has been frozen, do not use it. Keep it away from children and pets, and avoid storing it in areas where temperature changes quickly, such as a car, windowsill, or checked luggage.

When preparing to travel, keep the carton with the medication and carry documentation from your clinic when possible. An insulated bag may be needed to maintain appropriate temperature during transit, but the syringe should not touch ice directly. If travel crosses time zones or disrupts infusion scheduling, ask the oncology team to confirm the correct injection window in advance.

Orders may use prompt, express shipping when appropriate for the product and handling requirements. Plan ahead when chemotherapy cycles are scheduled, since temperature-sensitive injectable medicines should not be left unattended after arrival.

Side Effects, Warnings, and Monitoring

Bone pain is one of the most common side effects of Neulasta. Some people also report pain in the arms or legs, headache, nausea, or redness and discomfort at the injection site. Bone pain can occur as the marrow becomes more active. Your care team can suggest suitable symptom relief based on your cancer treatment plan and other medicines.

Serious reactions are less common but need prompt attention. Seek urgent medical help for left upper abdominal pain or shoulder pain, which can be a warning sign of spleen problems. Report shortness of breath, wheezing, swelling, rash, dizziness, fever, or signs of infection. Pegfilgrastim products have been associated with serious allergic reactions, acute respiratory distress syndrome, splenic rupture, capillary leak syndrome, aortitis, and severe sickle cell crises in at-risk patients.

People with a prior serious allergic reaction to pegfilgrastim or filgrastim should not use Neulasta. Extra caution may be needed for those with sickle cell disease, existing spleen concerns, lung symptoms, or a history of severe hypersensitivity. Blood counts may be monitored during chemotherapy cycles, and unusually high white blood cell counts can occur.

Clinically important drug interactions are not common, but lithium may affect neutrophil release and may lead clinicians to monitor counts more closely. Vaccination timing, especially live vaccines, should be discussed with the oncology team during chemotherapy. Share all medicines, supplements, and over-the-counter products with the clinic so monitoring can be planned safely.

What to Expect During Treatment Cycles

Neulasta is intended to shorten the period when neutrophils are very low after certain chemotherapy regimens. That support may help reduce the risk of fever with neutropenia, but it does not remove the need to watch closely for infection. Fever during chemotherapy should be taken seriously, even if pegfilgrastim was used.

Bone pain, if it happens, often starts after the injection as marrow activity increases. The duration varies. Some people have mild discomfort, while others need guidance on pain control. Do not start new pain medicines without checking whether they are appropriate with your chemotherapy plan, platelet counts, kidney function, stomach risk, or other conditions.

Keep the clinic’s contact instructions easy to find. Call promptly for fever, chills, breathing problems, severe or unusual pain, faintness, swelling, rash, or any symptom your team has marked as urgent. Tracking injection time, symptoms, and temperature can make follow-up conversations clearer.

Neulasta Compared With Related Options

Neulasta is the brand name for pegfilgrastim. Other pegfilgrastim or G-CSF products may be considered depending on the treatment plan, local substitution rules, clinic preference, and availability. Biosimilar medicines are designed to be highly similar to a reference biologic, but any switch should be directed by the oncology team.

Some patients use the prefilled syringe, while others may receive related device formats under separate brand presentations. The prefilled syringe is different from an on-body injector because it is administered as a manual subcutaneous injection. The right format depends on clinic workflow, patient training, timing, storage, and comfort with injection handling.

If you want to browse supportive oncology therapies more broadly, the cancer medicines category can help orient related treatment areas. Educational articles in the cancer information section may also help you prepare practical questions for your care team, although individual treatment choices should always come from the oncology clinic.

Questions to Discuss With Your Oncology Team

• How high is my risk of febrile neutropenia with this chemotherapy regimen?
• What exact date and time should the injection be given after each infusion?
• Who will administer the syringe, and what training is needed?
• What side effects should I expect, and which symptoms are urgent?
• How should I manage bone pain if it occurs?
• How often will blood counts be monitored during this regimen?
• Are biosimilar or alternative G-CSF products appropriate if needed?
• What should I do if chemotherapy is delayed or the injection window is missed?

Authoritative Sources

For complete labeling, administration instructions, and safety information, consult official sources and your oncology team. The following references support the clinical points summarized above:

• Official prescribing information
• Manufacturer prefilled syringe instructions
• FDA label record

This content is for informational purposes only and is not a substitute for professional medical advice.